-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $18

Benzinga·09/03/2026 14:12:25
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $50 to $18.